SEC Form 4 · accession 0001140361-16-057973
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Eric Davis
Officer — EVP, General Counsel
Period of report
Mar 14, 2016
Accepted (ET)
Mar 16, 2016 · 12:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 14, 2016 | S | 1,996 | $86.212 | D | 76,190 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price in column 4 is the weighted average price. The price actually received ranged from $86.20 to $86.29. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff upon request, information regrading the number of shares sold at each price within the range.